CRT has exclusive rights to commercialise reagents arising from Cancer Research UK funded research. In addition, CRT has formed exclusive partnerships with other prestigious research institutes such as Birmingham University, University College London, Newcastle University and the Leukaemia Research Immunodiagnostics Unit of the University of Oxford.
Further partnerships worldwide are envisaged in order to create a continuously expanding and high quality source of antibodies created from cutting edge academic research.
The portfolio currently consists of over 600 monoclonal and polyclonal antibodies, as well as cell lines and transgenic models. Importantly, the research tools represent a diverse range of research interests and are not all oncology-focused. The portfolio is continually updated with our newest products and all our monoclonals are available for licensing. Many, in addition to the polyclonals, are available for sale.
Our long-standing relationships with all the major worldwide Life Science Reagents companies enable us to rapidly commercialise reagents within the portfolio. CRT’s dedicated Reagent Sales personnel, along with support from in-house legal and finance teams maintain hundreds of licensing agreements with over 60 companies.
© Cancer Research Technology 2012